Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lydia Atangcho"'
Autor:
Brett M. Babin, Lydia Atangcho, Mark B. van Eldijk, Michael J. Sweredoski, Annie Moradian, Sonja Hess, Tim Tolker-Nielsen, Dianne K. Newman, David A. Tirrell
Publikováno v:
mBio, Vol 8, Iss 5 (2017)
ABSTRACT Biofilm infections exhibit high tolerance against antibiotic treatment. The study of biofilms is complicated by phenotypic heterogeneity; biofilm subpopulations differ in their metabolic activities and their responses to antibiotics. Here, w
Externí odkaz:
https://doaj.org/article/304e4d5b63f845a58cf8ae5331b0818c
Autor:
Tejas Navaratna, Daniel Tresnak, Vivekanandan Subramanian, Lydia Atangcho, Marshall Case, Andrew Min, Mukesh Mahajan, Greg M. Thurber
Publikováno v:
J Am Chem Soc
Chemically stabilized peptides have attracted intense interest by academics and pharmaceutical companies due to their potential to hit currently ‘undruggable’ targets. However, engineering an optimal sequence, stabilizing linker location, and phy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d227360f64d893d234de4ed025ff9706
https://doi.org/10.1021/jacs.9b10716
https://doi.org/10.1021/jacs.9b10716
Autor:
Lydia Atangcho, Tejas Navaratna, Rahul Gopinath, Joshua A. Kritzer, Greg Gueorguiev, Mukesh Mahajan, Greg M. Thurber, Kirsten Deprey, Marshall Case, Hannah Levy
Publikováno v:
SSRN Electronic Journal.
Nearly two-thirds of all disease-associated proteins are ‘undruggable’ by modern therapeutics, meaning they are inside cells, out of the reach of biologics, but lack small molecule binding pockets. Stabilized peptides have the potential to hit th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::194c4172fb3e4f2a4473aaed5257fe28
https://doi.org/10.2139/ssrn.3596598
https://doi.org/10.2139/ssrn.3596598
Publikováno v:
Trends in biochemical sciences. 44(3)
Stabilized peptide therapeutics have the potential to hit currently undruggable targets, dramatically expanding the druggable genome. However, major obstacles to their development include poor intracellular delivery, rapid degradation, low target aff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7704bb71922f8e72e9abf785e86736a9
https://pubmed.ncbi.nlm.nih.gov/30563724
https://pubmed.ncbi.nlm.nih.gov/30563724
Autor:
Marcian E. Van Dort, Brian D. Ross, Lydia Atangcho, April A. Apfelbaum, Charles A. Nino, Cagri G. Besirli, Stefanie Galbán, Gary D. Luker, Greg M. Thurber, Hao Hong
The structure-based design of a new single entity, MEK/PI3K bifunctional inhibitor (7, ST-168), which displays improved MEK1 and PI3K isoform inhibition, is described. ST-168 demonstrated a 2.2-fold improvement in MEK1 inhibition and a 2.8-, 2.7-, 23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6610ceea037a028e2992f017b3078f9c
https://europepmc.org/articles/PMC5554897/
https://europepmc.org/articles/PMC5554897/
Publikováno v:
Molecular imaging and biology. 17(6)
Near-infrared (NIR) fluorescence imaging is widely used for tracking antibodies and biomolecules in vivo. Clinical and preclinical applications include intraoperative imaging, tracking therapeutics, and fluorescent labeling as a surrogate for subsequ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b22892f77d7a160bb7d42913e7f0096e
https://pubmed.ncbi.nlm.nih.gov/25869081
https://pubmed.ncbi.nlm.nih.gov/25869081